A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: Treatment of involuntary emotional expression disorder

[1]  C. Sánchez,et al.  Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression , 1997, Psychopharmacology.

[2]  R. Matsumoto.  Sigma Receptors: Chemistry, Cell Biology And Clinical Implications , 2007 .

[3]  L. Werling,et al.  Modulation of Classical Neurotransmitter Systems by σ Receptors , 2007 .

[4]  Daniel Weintraub,et al.  Defining and Diagnosing Involuntary Emotional Expression Disorder , 2006, CNS Spectrums.

[5]  K. Metters,et al.  Binding of [3H]cimetidine to rat brain tissue , 1980, Agents and Actions.

[6]  S. Bunn,et al.  Effects of thyroid status on presynapticα2-adrenoceptor function andβ-adrenoceptor binding in the rat brain , 2005, Journal of Neural Transmission.

[7]  R. Thisted,et al.  Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine , 2004, Neurology.

[8]  E. Sellers,et al.  Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers , 2004, Journal of clinical pharmacology.

[9]  W. Danysz,et al.  Brain Penetration and In Vivo Recovery of NMDA Receptor Antagonists Amantadine and Memantine: A Quantitative Microdialysis Study , 1999, Pharmaceutical Research.

[10]  L. Werling,et al.  Acute and chronic effects of nicotine on serotonin uptake in prefrontal cortex and hippocampus of rats , 2003, Synapse.

[11]  W. Slikker,et al.  Adolescent nicotine administration alters serotonin receptors and cell signaling mediated through adenylyl cyclase , 2002, Brain Research.

[12]  D. Mash,et al.  Dopamine transport function is elevated in cocaine users , 2002, Journal of neurochemistry.

[13]  G. Miller,et al.  Transgenic expression of a mutant glycine receptor decreases alcohol sensitivity of mice. , 2002, The Journal of pharmacology and experimental therapeutics.

[14]  A R Damasio,et al.  Pathological laughter and crying: a link to the cerebellum. , 2001, Brain : a journal of neurology.

[15]  N. Bowery,et al.  Allosteric modulation of [3H]‐CGP39653 binding through the glycine site of the NMDA receptor: further studies in rat and human brain , 2001, British journal of pharmacology.

[16]  Weimin Hong,et al.  Evidence that the σ1 receptor is not directly coupled to G proteins , 2000 .

[17]  M. Rogawski,et al.  Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents – toward an understanding of their favorable tolerability , 2000, Amino Acids.

[18]  Yueh-Ching Chou,et al.  Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan , 1999, Brain Research.

[19]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[20]  R. Bridges,et al.  Irreversible Inhibition of High‐Affinity [3H]Kainate Binding by a Novel Photoactivatable Analogue: (2′S,3′S,4′R)‐2′‐Carboxy‐4′‐(2‐Diazo‐1‐Oxo‐3,3,3‐Trifluoropropyl)‐3′‐Pyrrolidinyl Acetate , 1997, Journal of neurochemistry.

[21]  F. Tortella,et al.  An autoradiographic study of dextromethorphan high‐affinity binding sites in rat brain: sodium‐dependency and colocalization with paroxetine , 1997, British journal of pharmacology.

[22]  H S Chen,et al.  Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism. , 1997, The Journal of physiology.

[23]  G. Steinberg,et al.  Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. , 1996, Journal of neurosurgery.

[24]  C. Parsons,et al.  Zinc changes AMPA receptor properties: Results of binding studies and patch clamp recordings , 1996, Neuropharmacology.

[25]  S. Deben,et al.  Functional and Binding Properties of σ Receptors in Rat Cerebellum , 1995 .

[26]  J. Kornhuber,et al.  Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man , 1995, Neuroscience Letters.

[27]  K. Kellar,et al.  Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. , 1995, Molecular pharmacology.

[28]  E. Meier,et al.  Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. , 1995, Journal of medicinal chemistry.

[29]  K. Kovács,et al.  Density of NMDA‐Coupled and Uncoupled 1‐[1‐(2‐[3H]Thienyl)cyclohexyl]piperidine Recognition Sites in the Brain and Spinal Cord: Differential Effects of NMDA Agonists and Antagonists , 1994, Journal of neurochemistry.

[30]  E. Richelson.  Pharmacology of antidepressants--characteristics of the ideal drug. , 1994, Mayo Clinic proceedings.

[31]  R. Rosenthal,et al.  Increased Activation of L‐Type Voltage‐Dependent Calcium Channels Is Associated with Glycine Enhancement of N‐Methyl‐d‐Aspartate‐Stimulated Dopamine Release in Global Cerebral Ischemia/Reperfusion , 1994, Journal of neurochemistry.

[32]  E. Wong,et al.  Different densities of 5-HT3 receptors are labeled by [3H]quipazine, [3H]GR 65630 and [3H]geanisetron , 1993, Neuropharmacology.

[33]  P. Pflimlin,et al.  Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. , 1993, European journal of pharmacology.

[34]  R. DeLaPaz,et al.  Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile. , 1993, Neurological research.

[35]  D. Hosford,et al.  Increased number of GABAB receptors in the lethargic (lh/lh) mouse model of absence epilepsy , 1993, Brain Research.

[36]  G. F. Steinfels,et al.  DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine HBr], a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles. , 1992, The Journal of pharmacology and experimental therapeutics.

[37]  K. Sudoh,et al.  Characterization of [3H]YM617, R-(-)-5-[2-[[2[ethoxyring(n)-3H](o-ethoxyphenoxy)ethyl]amino]- propyl]-2-methoxybenzenesulfonamide HCl, a potent and selective alpha-1 adrenoceptor radioligand. , 1992, The Journal of pharmacology and experimental therapeutics.

[38]  S. Tejani-butt.  [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. , 1992, The Journal of pharmacology and experimental therapeutics.

[39]  E. Wong,et al.  Identification of a novel NMDA receptor in rat cerebellum. , 1991, European journal of pharmacology.

[40]  Y. Hattori,et al.  Identification and characterization of histamine H1‐ and H2‐receptors in guinea‐pig left atrial membranes by [3H]‐mepyramine and [3H]‐tiotidine binding , 1991, British journal of pharmacology.

[41]  K. Baimbridge,et al.  Dextromethorphan and phencyclidine receptor ligands: Differential effects on K+- and NMDA-evoked increases in cytosolic free Ca2+ concentration , 1991, Neuroscience Letters.

[42]  M. Johnston,et al.  Pharmacology of N‐methyl‐D‐aspartate‐induced brain injury in an in vivo perinatal rat model , 1990, Synapse.

[43]  F. Tortella,et al.  Dextromethorphan and neuromodulation: old drug coughs up new activities. , 1989, Trends in pharmacological sciences.

[44]  D. Greenberg,et al.  Antagonist drug selectivity for radioligand binding sites on voltage-gated and N-methyl-d-aspartate receptor-gated Ca2+ channels , 1989, Neuroscience Letters.

[45]  P. Canoll,et al.  Dextromethorphan and sigma ligands: common sites but diverse effects. , 1989, Life sciences.

[46]  R. Kostrzewa,et al.  Impaired ontogeny of striatal dopamine D1 and D2 binding sites after postnatal treatment of rats with SCH-23390 and spiroperidol. , 1989, Brain research. Developmental brain research.

[47]  D. Greenberg,et al.  Dextromethorphan and dextrorphan as calcium channel antagonists , 1988, Brain Research.

[48]  D. Choi,et al.  Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons. , 1987, The Journal of pharmacology and experimental therapeutics.

[49]  G. Wooten,et al.  Effects of sodium on cell surface and intracellular 3H-naloxone binding sites. , 1987, Life sciences.

[50]  D. Choi.  Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity , 1987, Brain Research.

[51]  T. Inaba,et al.  Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. , 1986, British journal of clinical pharmacology.

[52]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[53]  S. Snyder,et al.  Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1- propyl)piperidine , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[54]  P. Sever,et al.  Heterogeneity of mammalian α2-adrenoceptors delineated by [3H]yohimbine binding , 1986 .

[55]  L. M. Zhang,et al.  Dextrorphan: an antagonist for phencyclidine receptor. , 1986, NIDA research monograph.

[56]  J. Bircher,et al.  Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[57]  K. Kuriyama,et al.  Some characteristics of [3H]muscimol binding to synaptic membrane from rat brain , 1980, Brain Research.

[58]  S. Snyder,et al.  The glycine synaptic receptor: evidence that strychnine binding is associated with the ionic conductance mechanism. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[59]  S. Snyder,et al.  Muscarinic cholinergic binding in rat brain. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[60]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .